Market News AIOpen the app

LNTH stock news · Lantheus Holdings, Inc.

Stories about Lantheus Holdings, Inc. (LNTH) from the last 90 days, each explained in plain English with whether the news reads good or bad for the company.

Get alerts for LNTH

Follow Lantheus Holdings, Inc. (LNTH) free. When we publish a story about it, you get the plain-English explanation as an alert.

Get alerts for LNTH
Free on the App Store and Google Play, or on the web.
  1. Nov 9, 2026, 7:20 PM ET · Market

    PharmaLogic is buying Lantheus' CDMO business and its Springfield manufacturing plant.

    Neutral

    Lantheus agreed to sell its drug-making business and Springfield site, while keeping a long-term supply deal for lutetium Lu 177 dotatate. The undisclosed terms leave its outlook little changed.

  2. Aug 14, 2026, 12:24 PM ET · Trial

    Lantheus' Tauklarify gains FDA approval for use in Alzheimer's diagnostic procedures.

    Good for LNTH

    The FDA's approval of Lantheus' Tauklarify for Alzheimer's diagnostics is a pivotal development that is expected to boost the company's market presence and support its ongoing therapeutic programs. This approval not only validates the efficacy of the imaging agent but also positions Lantheus favorably in the growing Alzheimer's treatment market.